Structural Analysis on the Pathologic Mutant Glucocorticoid Receptor Ligand-Binding Domains. 2016

Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
Bioinformatics and Computational Biosciences Branch (D.E.H.), Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852; Program in Reproductive and Adult Endocrinology (S.S., T.M., T.K.), Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892; Department of Pediatrics (S.S.), Asahikawa Medical University, Asahikawa 078-8510, Japan; Division of Endocrinology, Metabolism and Diabetes (E.C.), First Department of Pediatrics, University of Athens Medical School, "Aghia Sophia" Children's Hospital, Athens 11527, Greece; and Department of Experimental Therapeutics (T.K.), Division of Experimental Biology, Sidra Medical and Research Center, Doha, Qatar.

Glucocorticoid receptor (GR) gene mutations may cause familial or sporadic generalized glucocorticoid resistance syndrome. Most of the missense forms distribute in the ligand-binding domain and impair its ligand-binding activity and formation of the activation function (AF)-2 that binds LXXLL motif-containing coactivators. We performed molecular dynamics simulations to ligand-binding domain of pathologic GR mutants to reveal their structural defects. Several calculated parameters including interaction energy for dexamethasone or the LXXLL peptide indicate that destruction of ligand-binding pocket (LBP) is a primary character. Their LBP defects are driven primarily by loss/reduction of the electrostatic interaction formed by R611 and T739 of the receptor to dexamethasone and a subsequent conformational mismatch, which deacylcortivazol resolves with its large phenylpyrazole moiety and efficiently stimulates transcriptional activity of the mutant receptors with LBP defect. Reduced affinity of the LXXLL peptide to AF-2 is caused mainly by disruption of the electrostatic bonds to the noncore leucine residues of this peptide that determine the peptide's specificity to GR, as well as by reduced noncovalent interaction against core leucines and subsequent exposure of the AF-2 surface to solvent. The results reveal molecular defects of pathologic mutant receptors and provide important insights to the actions of wild-type GR.

UI MeSH Term Description Entries
D007930 Leucine An essential branched-chain amino acid important for hemoglobin formation. L-Leucine,Leucine, L-Isomer,L-Isomer Leucine,Leucine, L Isomer
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011281 Pregnatrienes Pregnane derivatives containing three double bonds in the ring structures.
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011965 Receptors, Glucocorticoid Cytoplasmic proteins that specifically bind glucocorticoids and mediate their cellular effects. The glucocorticoid receptor-glucocorticoid complex acts in the nucleus to induce transcription of DNA. Glucocorticoids were named for their actions on blood glucose concentration, but they have equally important effects on protein and fat metabolism. Cortisol is the most important example. Corticoid Type II Receptor,Glucocorticoid Receptors,Glucocorticoids Receptor,Corticoid II Receptor,Corticoid Type II Receptors,Glucocorticoid Receptor,Receptors, Corticoid II,Receptors, Corticoid Type II,Receptors, Glucocorticoids,Corticoid II Receptors,Glucocorticoids Receptors,Receptor, Corticoid II,Receptor, Glucocorticoid,Receptor, Glucocorticoids

Related Publications

Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
February 1991, The Journal of biological chemistry,
Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
June 1993, Annals of the New York Academy of Sciences,
Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
August 2007, Biochemical Society transactions,
Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
February 2000, FEBS letters,
Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
March 1992, The Journal of steroid biochemistry and molecular biology,
Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
February 2020, Journal of chemical information and modeling,
Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
January 1999, Annual review of biochemistry,
Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
November 2019, Journal of molecular graphics & modelling,
Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
June 1990, Journal of steroid biochemistry,
Darrell E Hurt, and Shigeru Suzuki, and Takafumi Mayama, and Evangelia Charmandari, and Tomoshige Kino
April 2007, Molecular and cellular biology,
Copied contents to your clipboard!